Huakang Biomedical Holdings Company Limited provided preliminary unaudited consolidated earnings guidance for the nine months ended September 30, 2020. The company group is expected to record a loss attributable to owners of the company of approximately RMB 6.6 million for the nine months ended 30 September 2020 as compared with the profit attributable to owners of the company of approximately RMB 1.7 million for the nine months ended 30 September 2019. The board believes that the turning from profit in the corresponding period to loss in the current period was mainly attributable to (i) the decline in sales revenue in the markets within the People's Republic of China of approximately RMB 4.3 million as since the outbreak of the novel coronavirus (COVID-19) epidemic, a number of provinces and municipalities in the PRC have taken emergency public health measures and various actions to prevent the spread of the Epidemic, including crowd-control and/or stay-home policies or orders and in addition, the Epidemic also led the Group to halt productions and sales for around five weeks; and (ii) recognition of equity-settled share option expenses for the share options granted on 9 April 2020 of approximately RMB 2.7 million.